Anion carriers as potential treatments for cystic fibrosis: transport in cystic fibrosis cells, and additivity to channel-targeting drugs

Hongyu Li, Hennie Valkenier, Abigail Thorne, Christopher M Dias, James A Cooper, Marion Keiffer, Nathalie Busschaert, Philip A. Gale, David N Sheppard, Anthony P Davis

Research output: Contribution to journalArticle (Academic Journal)

118 Downloads (Pure)


Defective anion transport is a hallmark of the genetic disease cystic fibrosis (CF). One approach to restore anion transport to CF cells utilises alternative pathways for transmembrane anion transport, including artificial anion carriers (anionophores). Here, we screened 22 anionophores for biological activity using fluorescence emission from the halidesensitive yellow fluorescent protein. Three compounds possessed anion transport activity similar to or greater than that of a bis-(p-nitrophenyl)ureidodecalin previously shown to have promising biological activity. Anion transport by these anionophores was concentration-dependent and persistent. All four anionophores mediated anion transport in CF cells, and their activity was additive to rescue of the predominant disease-causing variant F508del-CFTR using the clinically licensed drugs lumacaftor and ivacaftor. Toxicity was variable but minimal at the lower end. The results provide further evidence that anionophores, by themselves or together with other treatments that restore anion transport, offer a potential therapeutic strategy for CF.
Original languageEnglish
Pages (from-to)9663-9672
Number of pages10
JournalChemical Science
Early online date2 Oct 2019
Publication statusE-pub ahead of print - 2 Oct 2019


Structured keywords

  • BCS and TECS CDTs

Cite this